Abstracts tagged "biopsies and lupus nephritis"

Abstract Number: 1921 • 2017 ACR/ARHP Annual Meeting
Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis
Samar Soliman^1,2, Fatma Mohamed³, Faten Ismail³, Ramesh Saxena⁴ and Chandra Mohan², ¹Rheumatology and rehabilitation, University of Minya, Minya, Egypt, ²Biomedical Engineering, University of Houston, Houston, TX, ³Rheumatology and Rehabilitation, University of Minya, Minya, Egypt, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study is to investigate how urinary angiostatin, VCAM-1 and established measures of renal function relate to specific histologic findings in…
Abstract Number: 611 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Transjugular Renal Biopsy In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Retrospective Monocentric Study Of 91 Procedures
Alexis Mathian¹, Maud Cazenave², Laurent Arnaud³, Nathalie Costedoat-Chalumeau⁴, Du Boutin-LE Thi Huong⁵, Ahlem Chaib⁵, Fleur Cohen-Aubart⁶, Julien Haroche³, Miguel Hié⁵, Makoto Miyara⁵, Philippe Rouvier⁷, Jean-Charles Piette⁸, Philippe Cluzel⁹ and Zahir Amoura¹⁰, ¹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Internal Medicine, Paris, France, ²Service de médecine interne 2, Centre de référence National pour le Lupus et le Syndrome des antiphospholipides, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, ³Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁷Service d'anatomie pathologie, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, ⁸Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁹Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: Percutaneous renal biopsy requires a long duration discontinuation of antithrombotic treatment which can increase the risk of thrombosis in patient with Systemic Lupus Erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].